Clinical Trial Update: A Trial to Evaluate the Safety of Long Term Treatment With Nintedanib in Patients With Scleroderma Related Lung Fibrosis [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating the long-term safety of nintedanib in scleroderma-related lung fibrosis has completed and posted results in 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Scleroderma-related Lung Fibrosis
• Systemic Sclerosis-associated Interstitial Lung Disease

Drugs mentioned

• Nintedanib (nintedanib)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Lung Diseases, Interstitial | Phase 3 | Status: COMPLETED | Results posted: 2024-02-20